Stable peptide compositions
By using low-level citrate buffer and EDTA in the polypeptide preparation, combined with appropriate pH and osmotic pressure, the problem of poor stability of the polypeptide at room temperature is solved, and the long-term storage and safe delivery of the polypeptide preparation is achieved, reducing side effects. risk.
Patent Information
- Application Number
- CN202411078100.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-07-10
- Filing Date
- 2018-02-20
- Publication Date
- 2024-11-19
AI Technical Summary
Existing polypeptide preparations are difficult to stabilize at room temperature and often require freezing and storage, resulting in short transportation and shelf life, and commonly used stabilizers and preservatives may cause side effects.
Using diluted polypeptide compositions containing low levels of citrate buffer and low levels of EDTA, a stable aqueous solution is formed by adjusting pH and osmotic pressure, reducing or without the use of surfactants and preservatives, provides sterile kits to achieve the peptide. long-term storage and delivery.
The stable storage and delivery of peptides at room temperature is achieved, which reduces the occurrence of side effects, extends the shelf life, and improves the safety and tolerance of peptides.
Smart Images

Figure CN118975979A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 530,565, filed on July 10, 2017, and U.S. Provisional Patent Application No. 62 / 461,467, filed on February 21, 2017, each of which is incorporated herein by reference in its entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
[0003] This invention was made with government support under R01EY024327 awarded by the National Institutes of Health. The government has certain rights in this application.
[0004] About Sequence Listing
[0005] The materials in the attached sequence listing are hereby incorporated by reference into this application. The attached sequence listing text file named TEAR.003WO.TXT was created on February 14, 2018 and is 7.18KB in size. The contents of the sequence listing are hereby incorporated by reference in their entirety. background
[0007] field
[0008] The present application relates to the fields of chemistry, biochemistry and medicine. More specifically, several embodiments of the present application relate to stable dilute peptide compositions and kits comprising such compositions. Specifically, several embodiments of the present application describe compositions comprising an aqueous solution of citrate, EDTA and peptides, which are stable at room temperature (e.g., 20° C. to 25° C.) and contain or do not contain a surfactant.
[0009] Related technical description
[0010] Polypeptides are increasingly being viewed as potential therapeutic agents. Therefore, there is an increasing interest in the exploration of polypeptides in pharmaceutical research and development. However, it is well known that polypeptides are difficult to formulate, and additives used to preserve or stabilize such formulations can lead to, for example, undesirable side effects. SUMMARY OF THE INVENTION
[0012] There is an unmet need for such peptide compositions: the peptide compositions provide therapeutic amounts of peptides, are stable at room temperature, and contain only trace amounts of stabilizers and / or preservatives or are completely free of stabilizers and / or preservatives. In order to meet such needs and other needs, several embodiments of the present application provide stable polypeptide compositions. Advantageously, in some embodiments, the peptide (or combination of peptides) is stable in the compositions of the present application, thereby allowing long-term storage and / or delivery over an extended period of time. Therefore, these peptide compositions are stable at non-refrigerated temperatures, do not require reconstitution, and are functional at a range of temperatures (including temperatures within the range of 0-30°C). In fact, some embodiments of the present application are based in part on the following surprising and unexpected findings: diluted peptide compositions comprising low levels of EDTA combined with low levels of citrate buffers are still effective after storage at room temperature, even if such compositions contain significantly lower levels of additives than are typically present in polypeptide compositions.
[0013] Some embodiments provide a composition (e.g., a liquid composition) comprising, consisting of, or consisting essentially of: about 0.00001%-0.1%, 0.001%-0.1% (e.g., 0.01% or 0.005% or 0.001%) of a polypeptide or a pharmaceutically acceptable salt thereof; about 0.03%-3% (e.g., 0.2888%) of a buffer; no or about 0.0001%-0.01% (e.g., 0% or 0.001%) of disodium EDTA; no or about 0.005%-0.5% (e.g., 0% or 0.05%) of tyloxapol and sodium chloride (e.g., 0.5%); wherein the pH of the composition is about 6.2 to about 6.8, and the osmotic pressure of the composition is about 150-500 mOsm / kg or more (e.g., 250 to 350 mOsm / kg). Liquid compositions include, but are not limited to, combinations, mixtures, solutions, gel compositions, and ointments.
[0014] In some embodiments, the buffer is a citrate buffer. In some embodiments, the citrate buffer comprises about 0.001%-0.1% (e.g., 0.0098%) of anhydrous citric acid and about 0.02%-2% (e.g., 0.279%) of sodium citrate dihydrate. In some embodiments, the pH of the composition is about 6.5.
[0015] In some embodiments, the osmotic pressure of the composition is about 280 to about 320 mOsm / kg. In some embodiments, the osmotic pressure of the composition is about 300 mOsm / kg. In some embodiments, the amount of NaCl is 0.4% and 0.6% (e.g., about 0.5%).
[0016] In some embodiments, the composition further comprises a paraben, such as methylparaben (eg, 0.04% or less). In alternative embodiments, no parabens or other preservatives are included. In some embodiments, the composition further comprises sodium chlorite.
[0017] Some embodiments provide test kits, comprising multiple sterile disposable containers, wherein each container includes a vessel for holding the composition. In some embodiments, the container includes a composition of about 0.03mL to about 1mL (for example, 0.040mL, 0.050mL, 0.060mL, 0.070mL, 0.075mL, 0.1mL, 0.15mL, 0.2mL, 0.25mL, 0.3mL, 0.35mL, 0.4mL, 0.45mL, 0.5mL, 0.6mL, 0.7mL, 0.8mL, 0.9mL). In some embodiments, the container is used for daily use, weekly use or longer-term use. In one embodiment, a container of 1mL-30mL is used. In some embodiments, the container is a dropper bottle or a gel / ointment tube. In some embodiments, the container includes a removable sealing top for sealing the vessel and a neck that the vessel is interconnected with the sealing top.
[0018] In some embodiments, the container is made of one or more of the following materials: polyvinyl chloride, polypropylene, polyethylene terephthalate, polyethylene terephthalate G, high density polyethylene, low density polyethylene, polybutylene terephthalate, polyurethane, polyethylene vinyl acetate, silicone, acrylonitrile butadiene styrene, polytetrafluoroethylene, polycarbonate, polystyrene, polymethyl methacrylate, polysulfone, polyvinylidene chloride, or a combination thereof. In some embodiments, glass containers and surfaces are provided that can reduce adhesion of the composition to the inner surface of the container.
[0019] In some embodiments, the polypeptide is Lacripep having SEQ ID NO: 1. TM or a pharmaceutically acceptable salt thereof. In some embodiments, the polypeptide has a sequence selected from SEQ ID NOs: 2-9, or a pharmaceutically acceptable salt thereof, or a fragment or fragments thereof. In some embodiments, the polypeptide or a pharmaceutically acceptable salt thereof has at least about 80%, 85%, 90%, 95%, or 98% sequence homology to SEQ ID NO: 1 or SEQ ID NOs: 2-9.
[0020] Some embodiments provide methods of administration comprising applying a composition (such as liquid eye drops) topically to the eye from a disposable container. Some embodiments provide methods of administration comprising applying a composition (such as sterile preservative-free liquid eye drops) topically to the eye from a disposable container.
[0021] Some embodiments provide a method of treating dry eye and / or primary Sjögren's syndrome, comprising administering a composition disclosed herein to the eye of a subject suffering from dry eye and / or primary Sjögren's syndrome, wherein the amount of the polypeptide or a pharmaceutically acceptable salt thereof is 0.005% or 0.01%, wherein the polypeptide has a sequence consisting of Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-NH2, wherein "Ac" represents an acetyl group and the C-terminus is amidated (SEQ ID NO: 1), and wherein one drop of the composition is administered to the eye of the subject up to three times a day. In some embodiments, administration improves the total fluorescein corneal staining (FCS) score (NEI / Industry Workshop 0-15 scale) in the subject's eye after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or after at least 6 weeks from the start of 4 weeks of treatment, compared to a baseline measurement before starting treatment. In some embodiments, administration improves one or more of the following:
[0022] Dryness of the eye after at least 2 weeks of treatment, or after at least 4 weeks of treatment, compared to baseline on a visual analogue scale;
[0023] SANDE after at least 2 weeks of treatment (overall score SANDE-1) compared with baseline measurement before starting treatment;
[0024] Mean SANDE score (overall score SANDE-1) after at least 2 weeks of treatment compared with baseline measurement before starting treatment;
[0025] Individual symptom assessments (momentary) after at least 2 weeks of treatment compared to baseline measurements before starting treatment;
[0026] Mean scores of individual symptom assessments after at least 2 weeks of treatment compared to baseline measurements before starting treatment (reflected);
[0027] LGCS in the subject's eyes after at least 2 weeks of treatment compared to baseline measurements before starting treatment;
[0028] Anesthetized tear secretion test (Schirmer test) in the subject's eyes after at least 2 weeks of treatment compared to baseline measurements before starting treatment;
[0029] TFBUT in the subject's eye after at least 2 weeks of treatment compared to baseline measurements before starting treatment;
[0030] FCS in the subject's eyes after at least 2 weeks of treatment compared to baseline measurements before starting treatment;
[0031] SANDE (SANDE-1 global score) at 1 week after at least 2 weeks of treatment, or at least 4 weeks of treatment, or after 4 weeks of treatment, compared with baseline measurement before starting treatment;
[0032] Individual symptoms (transient) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared to baseline measurements before starting treatment;
[0033] Mean score (SANDE-2 global score) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared with baseline measurement before starting treatment;
[0034] Mean scores on individual symptom assessments (reflected) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared to baseline measurements before starting treatment;
[0035] FCS and SANDE-1 and individual symptom assessments (momentary) after at least 2 weeks of treatment, or after at least 4 weeks of treatment compared to baseline measurements before initiation of treatment;
[0036] LGCS after at least 2 weeks of treatment, or after at least 4 weeks of treatment, compared with baseline measurement before starting treatment;
[0037] Anesthetized tear test results after at least 2 weeks of treatment, or after at least 4 weeks of treatment, compared to baseline measurements before starting treatment;
[0038] TFBUT after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared to the baseline measurement before starting treatment.
[0039] In some embodiments, administration of the composition to a group of subjects does not result in a statistically higher incidence of adverse events than the incidence of adverse events when a placebo is administered to a similar group of subjects. In some embodiments, administration of the composition to a group of subjects does not result in a statistically higher incidence of serious adverse events than the incidence of serious adverse events when a placebo is administered to a similar group of subjects. In some embodiments, the concentration of the polypeptide or its pharmaceutically acceptable salt is about 0.005%. In some embodiments, the concentration of the polypeptide or its pharmaceutically acceptable salt is about 0.01%. In some embodiments, the subject meets all of the following criteria:
[0040] Aged 18 or above;
[0041] A previous history or current diagnosis of primary Sjögren's syndrome documented according to the American-European Consensus Group Sjögren's syndrome criteria, with 4 of the 6 total criteria or 3 of the 4 signs;
[0042] If the subject is receiving systemic (oral) therapy for the treatment of Sjögren's syndrome, the subject must have been receiving stable systemic therapy, defined as the same therapy, for the immediately preceding 90 days;
[0043] A history of dry eye-related ocular symptoms and self-reported use of over-the-counter ocular lubricants in the past 120 days; and
[0044] Before starting treatment, all of the following criteria were met:
[0045] (a) Fluorescein corneal staining (FCS) total score ≥4 and <15 (where 0 = no staining) on the National Eye Institute (NEI) / Industry Workshop scale;
[0046] (b) symptom score ≥40 using the SANDE questionnaire;
[0047] (c) anesthesia tear secretion test score ≤ 5 mm wetting / 5 min;
[0048] (d) total score of lissamine green conjunctival staining (LGCS) ≥5 (where 0 = no staining) using the NEI / Industry Workshop Scale;
[0049] Subjects had to meet all 4 criteria in at least one and the same eye at the time of follow-up.
[0050] In some embodiments, the subject does not meet one or more of the following criteria:
[0051] Any active infectious eye condition;
[0052] Monocular or best-corrected visual acuity (BCVA), using corrective lenses when necessary, of +1.0 logMAR or worse, as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS);
[0053] Ocular inflammatory conditions not related to dry eye syndrome (e.g., conjunctivitis, keratitis, anterior blepharitis, etc.);
[0054] Clinical evidence of scarring ocular surface disease, such as scarring ocular pemphigoid or Stevens-Johnson syndrome;
[0055] During treatment with the composition, the use of any topical ophthalmic medication (including topical cyclosporine, and / or topical corticosteroids) should not be suspended;
[0056] Used within 60 days before starting treatment with the combination (topical ophthalmic cyclosporine);
[0057] Within 30 to 60 days before starting treatment with the composition, or within 60 days, (topical ophthalmic lifalast);
[0058] The subject's eye has a total fluorescein corneal staining (FCS) score = 15 or a score = 3 on the upper zone NEI / Industry Workshop scale, or the subject's eye has diffuse confluent staining FCS, filamentous, or obvious epithelial defects;
[0059] Active herpetic keratitis or an outbreak of herpetic keratitis within 365 days of starting treatment, or the subject is taking long-term oral antiviral medication for herpetic disease;
[0060] Do not suspend the use of contact lenses or avoid the use of contact lenses during treatment;
[0061] Have a history of collagen vascular disease, autoimmune disease, or rheumatic disease (e.g., lupus, rheumatoid arthritis, etc.) other than primary Sjögren's syndrome;
[0062] A history of or current anterior membrane dystrophy;
[0063] Have undergone corneal transplant or similar corneal surgery (DALK, DSEK, DMEK, etc.);
[0064] Have used or are planning to use amiodarone;
[0065] Changes in the dose of any of the following within 30 days prior to starting treatment or anticipated changes in the dose of any of the following: tetracycline, omega-3, or omega-6;
[0066] Changes in the doses of the following within 60 days before starting treatment and / or during treatment or anticipated changes in the doses of the following: anticholinergics, antidepressants, oral contraceptives, isotretinoin, oral systemic corticosteroids, oral systemic immunosuppressants;
[0067] Use of topical ophthalmic antihistamines, ophthalmic, inhaled or intranasal corticosteroids, topical or oral mast cell stabilizers, oral antihistamines, topical or nasal vasoconstrictors, topical ophthalmic nonsteroidal anti-inflammatory drugs, or topical ophthalmic antibiotics within 30 days before starting treatment and / or during the study;
[0068] In the subject's eye, punctal cautery has been performed within the past 90 days or a punctal plug has been changed (inserted or removed) prior to starting treatment;
[0069] The subject has had corneal refractive surgery (LASIK, PRK, RK) performed in the eye;
[0070] Any history of any surgical procedure on the ocular surface or eyelid within 365 days prior to starting treatment, and any history of intraocular surgery within 90 days prior to starting treatment;
[0071] Pregnancy or suspected pregnancy;
[0072] are breastfeeding or plan to breastfeed; and
[0073] Participation in a device or investigational drug research or clinical trial within 30 days of starting treatment.
[0074] In some embodiments of any composition, kit, or method disclosed herein, the polypeptide has a sequence consisting of Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-NH2, wherein "Ac" represents an acetyl group and the C-terminus is amidated (SEQ ID NO: 1). In some embodiments of any composition, kit, or method disclosed herein, the amount of the polypeptide or a pharmaceutically acceptable salt thereof is 0.01% or 0.005%. In some embodiments, the comparison with the baseline measurement before the start of treatment is instead of or also includes a comparison of the treatment with the polypeptide relative to the vehicle control. In some embodiments of any composition, kit, or method disclosed herein, the composition does not contain tyloxapol. In some embodiments of any composition, kit, or method disclosed herein, the composition does not contain EDTA. In some embodiments of any composition, kit, or method disclosed herein, after storing the composition at 5±3°C or 25±2°C and 25±5% relative humidity for 1 week, the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition. In some embodiments of any composition, kit, or method disclosed herein, after storing the composition at 25±2°C and 25±5% relative humidity for 2 weeks, the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition. In some embodiments of any composition, kit, or method disclosed herein, after storing the composition at 5±3°C or 25±2°C and 25±5% relative humidity for 1 month, the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition. In some embodiments of any composition, kit, or method disclosed herein, after storing the composition at 5±3°C for 2 months, the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition. In some embodiments of any composition, kit, or method disclosed herein, after storing the composition at 5±3°C or -20±5°C for 3 months, the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition. In some embodiments of any composition, kit, or method disclosed herein, after storing the composition at 5±3°C for 4 months, the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition. In some embodiments of any composition, kit, or method disclosed herein, after storing the composition at 5±3°C for 5 months, the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition.In some embodiments of any composition, kit, or method disclosed herein, in the composition, the composition retains at least about 99.5%, 99.9%, or 99.95% of the polypeptide in an undegraded form. In some embodiments of any composition, kit, or method disclosed herein, after the composition is stored at 5±3°C for 12 months, in the composition, the composition retains at least about 80% or 90% of the polypeptide in an undegraded form. BRIEF DESCRIPTION OF THE DRAWINGS
[0076] Figure 1 Display Lacripep TM Stability of (SEQ ID NO: 1) (0.001%) in phosphate buffered saline (PBS) pH 4.5 and 7.0. Lacripep was characterized by MALDI TOF mass spectrometry at time 0 (upper panel) and after 2 weeks (lower panel) at 60°C. TM After 2 weeks, the consumption of Lacripep in both pH 4.5 and 7.0 solutions was analyzed. TM A peak corresponding to the degradation product at 993.9 (m / e) (indicated by an arrow) becomes apparent. An additional degradation product is observed at about 2270 (m / e) (indicated by an arrow) in the solution at pH 4.5.
[0077] Figure 2 Display Lacripep TM (SEQ ID NO: 1) (0.001%) in citrate buffer at pH 6 and 6.5. Lacripep was characterized by MALDI TOF mass spectrometry at 60°C at time 0 (upper panel) and after 2 weeks (lower panel). TM After 2 weeks, Lacripep TM There is no change in the intensity of the peak (indicated by the arrow), and no significant increase in the lower mass-to-charge ratio peak. DETAILED DESCRIPTION OF THE INVENTION
[0079] definition
[0080] The following are illustrative definitions of terms used herein. Unless otherwise expressly stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art when reading the entire specification. Unless otherwise stated, all patents, applications, published applications, and other publications mentioned herein are incorporated by reference in their entirety.
[0081] As used herein, the term "about" refers to a number, value, number, frequency, percentage, amount, or weight that varies by + / - 10% relative to a reference number, value, number, frequency, percentage, amount, or weight.
[0082] Unless otherwise stated, when a percentage (%) value is used in this application, the value refers to a weight / weight percentage value.
[0083] As used herein, the term "tonicity agent" shall be given its ordinary meaning and shall include materials whose primary purpose is to change the osmotic pressure of the composition. Suitable tonicity agents include, but are not limited to, propylene glycol, polyethylene glycol, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, monosaccharides (such as dextrose, fructose, galactose), and / or simple polyols (such as sugar alcohols mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol, hydrogenated starch hydrolysates, glycerol, and combinations thereof.
[0084] The term "stabilizer" as used herein shall be given its usual meaning and shall include materials that inhibit chemical reactions with peptides. Stabilizers may include, for example, antioxidants such as sodium pyrosulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene, and combinations thereof.
[0085] The term "surfactant" as used herein should be given its usual meaning and should include amphiphilic molecules, which means that they contain a hydrophobic group (tail) and a hydrophilic group (head). Therefore, surfactants contain a water-insoluble (or oil-soluble) component and a water-soluble component. Surfactants used herein can be detergents, wetting agents, emulsifiers, foaming agents, or dispersants. In some embodiments, polypeptides can act as surfactants.
[0086] The term "chelating agent" as used herein shall be given its usual meaning and shall include compounds that can form two or more bonds with metal ions (i.e., polydentate ligands). Chelating agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), ethylenediamine, amino acids (such as glutamic acid and histidine), organic dibasic acids (such as oxalic acid, malonic acid, etc.), and pharmaceutically acceptable salts of the foregoing. In several embodiments, the chelating agent is EDTA or a pharmaceutically acceptable salt thereof. In some embodiments, polypeptides can act as chelating agents.
[0087] As used herein, the term "viscosity building agent" shall be given its ordinary meaning and shall include materials that affect the viscosity (centipoise, or Cp) of the composition. Examples of viscosity enhancing agents include, but are not limited to, polysaccharides such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextran, various polymers of the cellulose family (and their derivatives), vinyl polymers, and acrylic polymers. Non-limiting examples of viscosity building agents include polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG), and polyacrylic acid (PAA).
[0088] As used herein, the term "ophthalmically acceptable" shall be given its ordinary meaning and shall include materials that are compatible with ocular tissue; that is, it does not cause significant or undue adverse effects when in contact with ocular tissue.
[0089] As used herein, the terms "stable", "stability" or "stabilized" shall be given their ordinary meanings and shall include products and compositions that enhance the primary, secondary and / or tertiary structure of a polypeptide. In some embodiments, a stabilized composition may have an acceptable percentage of peptide degradation, or aggregation products after a given period of time. These peptide degradation products may be the result of, for example, oxidation and / or hydrolysis of the peptide.
[0090] As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably and should be given their ordinary meanings. Unless otherwise clear from the context, the above terms include polymers having at least two amino acids linked by a peptide bond. Thus, these terms include oligopeptides, analogs, derivatives, acetylated derivatives, glycosylated derivatives, pegylated derivatives, and the like.
[0091] The term "pharmaceutically acceptable salt" should be given its usual meaning, and should include salts of such compounds that do not cause significant stimulation to the organism to which it is administered and do not eliminate or significantly reduce the biological activity and properties of the compound. In some embodiments, the salt of the compound can enhance the biological activity and properties of the compound. In other embodiments, the salt can additionally enhance the structural integrity or chemical stability of the compound. In some embodiments, the salt is an acid addition salt of the compound. Pharmaceutical salts can be obtained by reacting the compound with an inorganic acid, such as a hydrohalic acid, (e.g., hydrochloric acid or hydrobromic acid), sulfuric acid, nitric acid, or phosphoric acid. Pharmaceutical salts can also be obtained by reacting the compound with an organic acid (e.g., an aliphatic or aromatic carboxylic acid or sulfonic acid, such as formic acid, acetic acid, succinic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, nicotinic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid or naphthalenesulfonic acid). Pharmaceutically acceptable salts can also be obtained by reacting a compound with a base to form a salt, such as an ammonium salt, an alkali metal salt (such as a sodium salt or a potassium salt), an alkaline earth metal salt (such as a calcium salt or a magnesium salt), a salt with an organic base (such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, C1-C7 alkylamine, cyclohexane, triethanolamine, ethylenediamine), and a salt with an amino acid (such as arginine and lysine). In some embodiments, the polypeptide is an acetate.
[0092] Advantages in several implementations
[0093] As described above and herein, several embodiments of the present application provide compositions that are stable at room temperature. In several embodiments, the composition has a reduced level of stabilizers and other additives, which may cause undesirable side effects, yet still provide desired stability. In some embodiments, the composition provides stability of up to 1, 3, 6, 12, 24 and 48 hours in eyes, nasal cavity, mouth, epithelium and other tissues. In some embodiments, the composition is formulated so that some or all of the ingredients do not evaporate after being applied to the eyes or other areas, are absorbed, discharged or otherwise eliminated, but remain stable and remain active for several hours (e.g., 1-3 hours, 3-6 hours, 6-12 hours, 12-24 hours and the range therein). In some embodiments, the composition comprises a peptide such as Lacripep TMOr other sequences identified herein, wherein the peptide is applied to the eye and the peptide is incorporated into the lipid layer of the tear covering the eye, or at the interface of the lipid component and the water component of the tear, wherein the peptide stabilizes the tear and remains in the tear for a period of at least 1-3 hours, at least 3-6 hours, or at least 12-24 hours, or greater than 24 hours. In several embodiments, this feature is particularly advantageous because it allows the active ingredient (such as the peptide) to remain stable and effective for a long time. In some embodiments, the reduced frequency of administration results in an overall reduced total load of the ingredient to sensitive areas of the body (such as the eye).
[0094] Although peptides are provided in several embodiments herein, other compounds may be used as active ingredients in addition to or in place of the peptides.
[0095] Peptides are highly selective and effective, relatively safe and well tolerated. Peptides are particularly suitable for compositions described herein because peptides may be chemically and physically unstable relative to certain small molecule-based therapeutic agents. For example, peptides are susceptible to hydrolysis, oxidation and aggregation. Peptide compositions are typically aqueous solutions containing active peptides together with many stabilizers, preservatives and other agents for maintaining peptide efficacy. Stabilizers, preservatives and other agents can maintain the chemical and / or structural integrity of the polypeptide, thereby retaining its efficacy. Some additives (such as stabilizers and preservatives) may cause undesirable side effects, including hypersensitivity, itching, and stinging or burning sensations. However, in order to maximize the shelf life of the peptide and maintain efficacy, these additives that result in the amount of undesirable results are required in most peptide compositions. Even in compositions with all these additives, the peptide therapeutic agent must usually be frozen, thereby making transportation difficult, and even in frozen conditions, the peptide therapeutic agent still has a short shelf life. Furthermore, as peptides degrade and / or aggregate over time (particularly by heating and cooling when removed from refrigeration to room temperature for use), the byproducts may not only be inactive, but they may also be toxic and / or immunogenic. Formulators may attempt to increase the potency of peptide compositions by increasing the amount of active peptide in the composition. However, increased peptide concentrations may also increase the incidence of peptide aggregation and inactivation.
[0096] Thus, several embodiments herein provide peptide compositions that provide therapeutic amounts of peptides that are stable at room temperature and contain reduced (e.g., only trace amounts) stabilizers and / or preservatives or no stabilizers and / or preservatives at all. In some embodiments, the peptide is selected from: (a) the amino acid sequence KQFIENGSEFAQKLLKKFS, Ac-KQFIENGSEFAQKLLKKFS-NH2, or Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-NH2, wherein "Ac" represents an acetyl group and the C-terminus is amidated (SEQ ID NO: 1), also referred to herein as "Lacripep TM ”; and (b) the amino acid sequence KQFIENGSEFAQKLLKKFSLLKPWA, Ac-KQFIENGSEFAQKLLKKFSLLKPWA-NH2, or Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-Leu-Leu-Lys-Pro-Trp-Ala-NH2, wherein “Ac” represents an acetyl group and the C-terminus is amidated (SEQ ID NO: 2). In other embodiments, the peptide has one of the following amino acid sequences or a fragment thereof, optionally with an acetylated N-terminus and / or an amidated C-terminus:
[0097] <210> SEQ ID NO: 3
[0098] <211> Length: 138
[0099] <212> Type: PRT
[0100] <213> Organism: Homo sapiens
[0101] <400> Sequence: 3
[0102]
[0103] <210> SEQ ID NO: 4 <211> Length: 119
[0104] <212> Type: PRT
[0105] <213> Organism: Homo sapiens <400> Sequence: 4
[0106]
[0107] <210> SEQ ID NO: 5 <211> Length: 114
[0108] <212> Type: PRT
[0109] <213> Organism: Homo sapiens <400> Sequence: 5
[0110]
[0111] <210> SEQ ID NO: 6 <211> Length: 114
[0112] <212> Type: PRT
[0113] <213> Organism: Homo sapiens <400> Sequence: 6
[0114]
[0115] <210> SEQ ID NO: 7 <211> Length: 109
[0116] <212> Type: PRT
[0117] <213> Organism: Homo sapiens
[0118] <400> Sequence: 7
[0119]
[0120] <210> SEQ ID NO: 8
[0121] <211> Length: 104
[0122] <212> Type: PRT
[0123] <213> Organism: Homo sapiens
[0124] <400> Sequence: 8
[0125]
[0126] <210> SEQ ID NO: 9
[0127] <211> Length: 14
[0128] <212> Type: PRT
[0129] <213> Organism: Homo sapiens
[0130] <400> Sequence: 9
[0131] <400> SEQUENCE:9
[0132]
[0133] In several embodiments, the peptide is represented by the amino acid sequence Ac-KQFIENGSEFAQKLLKKFS-NH2 or Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-NH2, wherein "Ac" represents an acetyl group and the C-terminus is amidated (SEQ ID NO: 1). In some embodiments, the peptide is Lacripep TM In some embodiments, the peptide is any one or more of SEQ ID NOs: 1-9.
[0134] Buffers and pH
[0135] Buffers stabilize the pH of a solution, i.e., resist changes in pH when acidic or basic materials are added to the solution. Suitable buffers for use in the compositions of the present invention include, but are not limited to, glycine hydrochloride, sodium acetate, phosphate buffered saline (PBS) (including monohydrogen phosphate and dihydrogen phosphate), citrate buffers (citric acid and sodium citrate), phosphate-citrate buffers, tris (hydroxymethyl) aminomethane (Tris), carbonate buffers (sodium carbonate and sodium bicarbonate), borate buffers, and combinations thereof.
[0136] In some embodiments, the buffer comprises one or more of sodium acetate, phosphate buffered saline (PBS), citrate buffer (citric acid and sodium citrate), and phosphate-citrate buffer. In some embodiments, the buffer is selected from sodium acetate, phosphate buffered saline (PBS), citrate buffer (citric acid and sodium citrate), and phosphate-citrate buffer.
[0137] In some embodiments, the amount of buffer is limited to less than 0.1, 0.2, 0.3, or 0.4%, or within a range defined by any two of the foregoing values.
[0138] In one embodiment, the buffer is citrate buffer (citric acid and sodium citrate). In one embodiment, the only buffer is citrate buffer and no other buffer is present in the composition.
[0139] In some embodiments, the pH of the composition is 6 to 7.4, 6.1 to 7.3, 6.2 to 7.2, 6.3 to 7.1, 6.4 to 7.0, 6.5 to 6.9, 6.6 to 6.8, or any pH therebetween.
[0140] In some embodiments, the pH of the composition is at or about 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, or in a range bounded by any two of the foregoing values.
[0141] In one embodiment, the pH of the composition is at or about 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, or 6.8.
[0142] If necessary, the pH of the composition can be adjusted by adding a solution of an acid or base. Any acid or base can be used, the conjugate of which is ophthalmologically acceptable. Acids include, for example, hydrochloric acid, and bases include, for example, sodium hydroxide and potassium hydroxide.
[0143] Chelating agents
[0144] In some embodiments, the composition further comprises one or more chelating agents. In some embodiments, the chelating agent is selected from ethylenediaminetetraacetic acid, disodium ethylenediaminetetraacetate (EDTA), ethylenediamine, amino acids (such as glutamic acid and histidine), organic diacids (such as oxalic acid, malonic acid, succinic acid, etc.), 3-dimercaptopropanesulfonic acid (DMPS), α-lipoic acid (ALA), 2,3-dimercaptopropanesulfonic acid (DMPS), fursultiamine (TTFD), penicillamine, dimercaptosuccinic acid (DMSA), combinations thereof, and pharmaceutically acceptable salts thereof.
[0145] In some embodiments, the chelating agent, as a non-limiting example EDTA or a pharmaceutically acceptable salt thereof, is present at 0.0001% to 0.1%, 0.0005% to 0.05%, 0.0006% to 0.04%, 0.0007% to 0.003%, 0.0008% to 0.002%, 0.0009% to 0.001%, or any value or range subsumed therein. In some embodiments, the chelating agent is present in an amount of or less than 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001%, or in an amount defined by any two of the foregoing values.
[0146] In some embodiments, the chelating agent, such as EDTA or others, or a pharmaceutically acceptable salt thereof, is present at less than about 0.05% or less than about 0.005% (eg, at about 0.001%).
[0147] Stabilizer
[0148] Buffer and chelating agent can stabilize the peptide component of composition by maintaining pH and reducing metal ion mediated peptide degradation.In some embodiments, in addition to buffer and / or chelating agent, composition also comprises one or more peptide stabilizers.In some embodiments, in addition to buffer and / or chelating agent, one or more stabilizers are selected from disaccharides, polysaccharides (e.g., hyaluronic acid), polyols, sugar alcohols, amino acids, proteins (e.g., serum albumin), and combinations thereof.In some embodiments, the non-limiting example of stabilizer includes trehalose, sucrose, mannitol, sorbitol, polysorbate 20, polysorbate 80, histidine, glycine and arginine, and combinations thereof.In one embodiment, in addition to buffer and / or chelating agent, composition does not comprise stabilizer.
[0149] Peptide degradation
[0150] Polypeptides are susceptible to physical and chemical degradation, such as aggregation, shearing, oxidation, deamidation, and hydrolysis. In fact, liquid peptide compositions have a high risk of physical and chemical instability during manufacture and storage. Reducing polypeptide degradation is particularly important for dilute peptide formulations that initially contain very small amounts of a particular peptide. Even the loss of very small amounts in the initial small amount can significantly affect the efficacy of the composition.
[0151] In some embodiments, the stability of the composition is determined by high performance liquid chromatography (HPLC). In some embodiments, the stability of the composition is determined using high performance liquid chromatography-mass spectrometry (HPLC-MS).
[0152] In some embodiments, the stability of the composition is determined after a sealed container of the composition has been in the dark or exposed to light at room temperature for days, weeks, or months (e.g., 1-24 days or months, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 days or months).
[0153] In some embodiments, the stability of the composition is determined after the sealed container of the composition has been in the dark or exposed to light for days, weeks, or months (e.g., 1-24 days or months, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 days or months) at a temperature between 2 and 8°C, such as 5°C, or any value therebetween.
[0154] In some embodiments, the stability of the composition is determined after the sealed container of the composition has been in the dark or exposed to light for days, weeks, or months (e.g., 1-24 days or months, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 days or months) at a temperature between -10 and -30°C, such as -25°C, or any value therebetween.
[0155] In some embodiments, composition stability is determined after a sealed container of the composition has been in the dark or exposed to light and moved from 2 to 8° C. (storage), or any value therebetween, to room temperature for 5 minutes, once, twice, or three times daily for 1-60 days.
[0156] In some embodiments, after exposure to one or more conditions described above and herein, the composition provides at least 99.99%, 99.95%, 99.9%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, or any value therebetween of the initial amount or activity of the polypeptide or its pharmaceutically acceptable salt in an intact, undegraded or non-aggregated form. In one embodiment, the amount or activity of the intact polypeptide or its pharmaceutically acceptable salt is at least 80%, 85%, 90% or 95% of the initial amount. In some embodiments, the amount or activity of the intact polypeptide or its pharmaceutically acceptable salt is at least 97% of the initial amount.
[0157] In some embodiments, after exposure to one or more conditions described above and herein, the composition comprises no more than 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or within the range defined by any two of the aforementioned values. Peptide aggregation products or peptide degradation products. In some embodiments, the composition comprises no more than about 15%, or no more than 20% inactive peptides.
[0158] In some embodiments, after exposure to one or more conditions described above and herein, the composition comprises no more than 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or the total amount of peptide degradation products and peptide aggregation products within the range defined by any two of the foregoing values.
[0159] In some embodiments, the composition comprises a very low level of buffer combined with a very low level of chelating agent. In some embodiments, the buffer is a citrate buffer and the chelating agent is EDTA. The combination of a low level of citrate buffer (e.g., 0.012% to 0.020%) and EDTA (e.g., 0.0005% to 0.005%) provides a surprising and unexpected benefit of stabilizing a composition containing low levels of peptides (e.g., 0.001 to 0.01%). Such stabilized compositions provide advantages of peptide compositions in manufacturing, transportation, storage, and use by reducing the aggregation and degradation of peptides, thereby maintaining the efficacy of the peptide compositions and reducing the accumulation of undesirable decomposition products in the compositions.
[0160] In some embodiments, the stabilized composition reduces the rate of formation of decomposition and / or aggregation products.
[0161] In some embodiments, the peptide is Lacripep TM. In some embodiments, the stabilized composition comprises less than about 5%, 4%, 3%, 2%, or about 1% of total degradation products. In some embodiments, the stabilized composition comprises no more than 0.25%, 0.5%, 0.75%, 1.0%, 1.25%, 1.5%, 1.75%, or 2.0% of any single degradation product. In some embodiments, the stabilized composition comprises less than about 5%, 4%, 3%, 2%, or about 1% of total degradation products and no more than 0.25%, 0.5%, 0.75%, 1.0%, 1.25%, 1.5%, 1.75%, or 2.0% of any single degradation product.
[0162] In some embodiments, the aggregation products include dimers, trimers, tetramers, or higher order peptide aggregates.
[0163] preservative
[0164] In some embodiments, the composition also includes one or more preservatives to prevent the growth of microorganisms in the composition. In some embodiments, the composition also includes one or more preservatives to keep the sterility of the composition. In some embodiments, the composition also includes one or more preservatives to prevent the growth of microorganisms and keep the sterility of the composition. However, in many embodiments, the preservative is provided with the amount reduced. In some embodiments, one or more preservatives are selected from benzalkonium chloride, cetylpyridinium chloride, chlorobutanol, benzododecinium bromide (benzododeciniumbromide), methylparaben, propylparaben, phenylethyl alcohol, sodium perborate, disodium edetate, chlorobutanol, sorbic acid, benzethonium chloride, sodium acetate, polyquaternium-1, phenylmercuric nitrate, phenylmercuric borate, sodium propionate, chlorhexidine, thimerosal, and their combination. In some embodiments, the composition does not contain a preservative. In some embodiments, the composition does not contain a preservative of detectable level. In some embodiments, the polypeptide may be self-preserving, ie, no additional preservatives are required to maintain the sterility of the composition.
[0165] In some embodiments, the preservative is present in an amount of 0.0001% to 1%, 0.01% to 0.9%, 0.05% to 0.8%, 0.1% to 0.7%, 0.2% to 0.3%, 0.4% to 0.5%, or any value subsumed therein. In some embodiments, the preservative is present at or in an amount less than 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, or 0.001%, or in an amount defined by any two of the foregoing values.
[0166] In some embodiments, the composition is sterile. In some embodiments, the composition is made from sterile ingredients in a sterile environment. In some embodiments, the composition is sterilized prior to packaging. In some embodiments, the composition is sterilized by one or more of the following steps: (1) adding one or more quaternary ammonium chlorides to the composition; (2) exposing the composition to ionizing radiation; (3) filtering the composition; (4) exposing the composition to ionizing radiation after packaging; and any combination of the foregoing. In some embodiments, filtering comprises passing the composition through a filter (including but not limited to a 0.22 micron filter having polydifluoroethylene, or other suitable membrane (e.g., polyethersulfone)).
[0167] In some embodiments, the peptide is provided in an amount that is bacteriostatic and / or bactericidal. In some embodiments, when one, two or three drops of the composition are administered to the surface of the eye, the amount of the peptide provided in the composition is bacteriostatic and / or bactericidal. In some embodiments, the peptide is bacteriostatic and / or bactericidal for Gram-positive and / or Gram-negative bacteria, for example, when administered to the eye. In some embodiments, in a standard bacteriological assay, relative to a control composition that does not contain the peptide, the amount of the peptide in the composition is sufficient to inhibit bacterial growth by at least 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%. In some embodiments, the bacteria of the bacteriological assay are selected from Pseudomonas aeruginosa, Escherichia coli, Staphylococcus epidermidis, Staphylococcus aureus or a combination thereof. In some embodiments, the bacteriological assay is selected from a bacterial growth assay, a SYTOX Green assay, a well diffusion assay, a broth or agar dilution assay, a time-kill test, an antimicrobial gradient assay, an ATP bioluminescence assay, or a propidium iodide flow cytometry assay. In some embodiments, the peptide provided in a bacteriostatic and / or bactericidal amount is Lacripep TM .
[0168] In some embodiments, the bacteriological assay is USP <51> Chapter assay or FDA authorized assay. For example, initially the product containers contain the peptide solution, each container is inoculated with one of the prepared and standardized inocula (e.g., Pseudomonas aeruginosa, Escherichia coli, Staphylococcus epidermidis, Staphylococcus aureus, or a combination thereof) and mixed. The volume of the suspended inoculum should be about 0.5% to 1.0% of the product volume, and the concentration of the test preparation immediately after inoculation is 1×10 5 Up to 1×10 6 Colony forming units (CFU) / mL product (as measured by, for example, plate counts, or another microbial enumeration test).
[0169] The inoculated containers were incubated at 22.5 ± 2.5 °C in a controlled environment and samples were taken at regular intervals (e.g., 7 days, 14 days, and 28 days). At each sampling, any changes in appearance were recorded and the CFU / mL was determined. The log of CFU / mL 10 The change in the value provides the change in log reduction over time. For bacteria, the product provides no less than 1.0 log reduction on day 7 relative to the initially calculated counts, no less than 3.0 log reduction on day 14 relative to the initial counts, no increase on day 28 relative to the day 14 counts, and no increase in yeast and mold relative to the initial counts. In some embodiments, the peptide provided in a bacteriostatic and / or bactericidal amount is Lacripep TM .
[0170] Surfactants
[0171] In some embodiments, the composition further comprises one or more surfactants. In some embodiments, the one or more surfactants are selected from detergents, wetting agents, emulsifiers, foaming agents, dispersants, and combinations thereof.
[0172] In some embodiments, the surfactant is an anionic surfactant. Anionic surfactants contain anionic functional groups in their heads, such as sulfates, sulfonates, phosphates and carboxylates. In some embodiments, the surfactant is a sulfate, sulfonate or phosphate, such as a sulfate. In some embodiments, the surfactant is selected from ammonium dodecyl sulfate and sodium dodecyl sulfate, such as sodium dodecyl sulfate (also known as SDS, sodium dodecyl sulfate) or composed of the above. In some embodiments, the surfactant is an alkyl ether sulfate, such as selected from polyoxyethylene alkyl sodium sulfate (also known as sodium dodecyl ether sulfate) and myristyl alcohol polyether sulfate sodium salt or composed of the above. In some embodiments, the surfactant is sodium docusate (such as sodium diisooctyl sulfosuccinate), perfluorooctane sulfonate (PFOS), perfluorobutane sulfonate, linear alkylbenzene sulfonate (LAB). In some embodiments, the surfactant is a carboxylate such as an alkyl carboxylate (soap), such as sodium stearate; sodium lauroyl sarcosinate and a fluorosurfactant based on a carboxylate, such as perfluorononanoate, perfluorooctanoate (PFOA or PFO). In some embodiments, the polypeptide contributes to the surfactant properties of the composition.
[0173] In some embodiments, the surfactant is a cationic surfactant, the charge of which may be pH-dependent, such as a primary, secondary or tertiary amine, e.g., octenidine dihydrochloride; or may contain a permanently charged quaternary ammonium cation, such as an alkyl trimethylammonium salt, e.g., hexadecyltrimethylammonium bromide (CTAB) or hexadecyltrimethylammonium chloride (CTAC); hexadecylpyridinium chloride (CPC); benzalkonium chloride (BAC); benzethonium chloride (BZT); 5-bromo-5-nitro-1,3-dioxane; dimethyldioctadecyl ammonium chloride; or dioctadecyldimethylammonium bromide (DODAB). In some embodiments, the surfactant is a zwitterionic surfactant (i.e., a cationic and anionic center attached to the same molecule at the same time). The cationic portion may be a cation based on a primary, secondary or tertiary amine or a quaternary ammonium. The anionic portion may be more varied and include sulfonates, such as in CHAPS (3-[(3-cholamidopropyl)dimethylamino]-1-propanesulfonate). Other anionic groups are sultaines, such as cocamidopropyl hydroxysultaine; betaines, for example cocamidopropyl betaine; phosphates, for example lecithin. In some embodiments, the surfactant may be a nonionic surfactant (without a charge).
[0174] Many long chain alcohols exhibit some surfactant properties and are provided herein as part of the compositions in some embodiments. Notable among these are the fatty alcohols cetyl alcohol, stearyl alcohol and cetostearyl alcohol (consisting primarily of cetyl alcohol and stearyl alcohol) and oleyl alcohol. Other surfactants include cocamide MEA, cocamide DEA, dodecyl dimethylamine oxide and polyoxyethylene tallow amine (POEA). Examples of nonionic surfactants include polyoxyethylene glycol alkyl ethers, such as octyl glycol monododecyl ether or pentyl glycol monododecyl ether; polyoxypropylene glycol alkyl ethers; glucoside alkyl ethers, such as decyl glucoside, dodecyl glucoside or octyl glucoside; polyoxyethylene glycol octylphenol ethers, such as Triton X-100; polyoxyethylene glycol alkylphenol ethers, such as nonoxynol-9; glycerol alkyl esters, such as glyceryl laurate; polyoxyethylene glycol sorbitan alkyl esters (polysorbates); sorbitan alkyl esters (spans); block copolymers of polyethylene glycol and polypropylene glycol, or poloxamers.
[0175] In some embodiments, the composition may contain one or more ingredients found in artificial tears in an amount known in the art, including, but not limited to: carboxymethylcellulose, polyvinyl alcohol, hydroxypropyl methylcellulose (also known as HPMC or hydroxypropyl methylcellulose), hydroxypropyl cellulose, hydroxyethyl cellulose (HEC) and hyaluronic acid (also known as hyaluronic acid, HA), and combinations thereof. In some embodiments, the composition does not contain any of the aforementioned artificial tears ingredients.
[0176] In some embodiments, the surfactant is another peptide or protein. In some embodiments, as a non-limiting example, the surfactant is human serum albumin. In some embodiments, as another non-limiting example, the surfactant is Lacripep TM .
[0177] In several embodiments, the surfactant is tyloxapol (formaldehyde; ethylene oxide; 4-(2,4,4-trimethylpentan-2-yl)phenol). In one embodiment, the only surfactant is tyloxapol, and no other surfactants are present in the composition.
[0178] In some embodiments, the surfactant (tyloxapol as a non-limiting example) is present in an amount of 0.01% to 1%, 0.05% to 0.9%, 0.1% to 0.8%, 0.2% to 0.7%, 0.3% to 0.6%, 0.4% or 0.5%, or any value subsumed therein. In some embodiments, the surfactant is present at or less than 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, or 0.001%, or in an amount defined by any two of the foregoing values.
[0179] In some embodiments, the composition contains no surfactant. In some embodiments, the composition contains no detectable levels of surfactant.
[0180] Tonicity Agents and Osmolarity
[0181] In some embodiments, the composition further comprises one or more tonicity agents. Such tonicity agents are any polypeptides or buffers with tonicity regulating effects. In some embodiments, one or more tonicity agents are selected from propylene glycol, polyethylene glycol, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, monosaccharides (such as dextrose, fructose, galactose), and / or simple polyols (such as sugar alcohols, mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol, hydrogenated starch hydrolysate, glycerol, and combinations thereof).
[0182] In some embodiments, the one or more tonicity agents are selected from sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose, mannitol, and combinations thereof.
[0183] In some embodiments, the tonicity agent is sodium chloride. In some embodiments, sodium chloride is present in an amount of 0.01% to 1%, 0.05% to 0.9%, 0.1% to 0.8%, 0.2% to 0.75%, 0.3% to 0.7%, 0.4% to 0.6%, or any value subsumed therein. In some embodiments, sodium chloride is present at or about 1%, 0.95%, 0.9%, 0.85%, 0.8%, 0.75%, 0.7%, 0.65%, 0.6%, 0.55%, 0.5%, 0.45%, 0.4%, 0.35%, 0.3%, 0.25%, 0.2%, 0.15%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, or 0.01%, or in a range defined by any two of the foregoing values.
[0184] In some embodiments, the only tonicity agent is sodium chloride, and no other tonicity agents are present in the composition.
[0185] In some embodiments, tonicity agent (as a non-limiting example sodium chloride) is added to the composition to adjust the osmotic pressure to the desired level. In some embodiments, the osmotic pressure of the composition is about 150 to about 400mOsm / kg, about 170 to about 380mOsm / kg, about 190 to about 360mOsm / kg, about 210 to about 340mOsm / kg, about 230 to about 320mOsm / kg, about 250 to about 300mOsm / kg, about 270 to about 280mOsm / kg or any value therebetween. In some embodiments, the osmotic pressure of the composition is about 250 to about 350mOsm / kg, about 260 to about 340mOsm / kg, about 270 to about 330mOsm / kg, about 280 to about 320mOsm / kg, about 290 to about 310mOsm / kg, or any value therebetween.
[0186] In some embodiments, the osmolality of the composition is at or about 150 mOsm / kg, 160 mOsm / kg, 170 mOsm / kg, 180 mOsm / kg, 190 mOsm / kg, 200 mOsm / kg, 210 mOsm / kg, 220 mOsm / kg, 230 mOsm / kg, 240 mOsm / kg, 250 mOsm / kg, 260 mOsm / kg, 270 mOsm / kg, 280 mOsm / kg, 290 mOsm / kg, 300 mOsm / kg, 310 mOsm / kg, 320 mOsm / kg, 330 mOsm / kg, 340 mOsm / kg, or 350 mOsm / kg, or is within a range defined by any two of the foregoing values.
[0187] In some embodiments, the osmotic pressure of the composition is about 280mOsm / kg to about 320mOsm / kg. In one embodiment, the osmotic pressure of the composition is about 300mOsm / kg. In some embodiments, the osmotic pressure of the solution is adjusted to the desired level with NaCl. In one embodiment, the composition is isotonic or nearly isotonic with human tears.
[0188] Peptides and other ingredients
[0189] In some embodiments, the polypeptide or a pharmaceutically acceptable salt thereof has 10 to 150 amino acids; 10 to 50 amino acids; 100 to 150 amino acids; 30 to 70 amino acids; or any number of amino acids contained therein. In some embodiments, the polypeptide or a pharmaceutically acceptable salt thereof has 10 to 30 amino acids, 11 to 29 amino acids, 12 to 28 amino acids, 13 to 27 amino acids, 14 to 26 amino acids, 15 to 25 amino acids, 16 to 24 amino acids, 17 to 23 amino acids, 18 to 22 amino acids, 19 to 21 amino acids; or any number of amino acids contained therein. In some embodiments, the polypeptide, or a pharmaceutically acceptable salt thereof, is or is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length, or in a range defined by any two of the foregoing values.
[0190] In some embodiments, the C-terminus of a polypeptide or a pharmaceutically acceptable salt thereof is amidated. In some embodiments, the N-terminus of a polypeptide or a pharmaceutically acceptable salt thereof is acetylated. In some embodiments, one or more side chains of a polypeptide or a pharmaceutically acceptable salt thereof are acetylated. In some embodiments, one or more side chains of a polypeptide or a pharmaceutically acceptable salt thereof are amidated. In some embodiments, the N-terminus of a polypeptide or a pharmaceutically acceptable salt thereof is acetylated, and the C-terminus of a polypeptide or a pharmaceutically acceptable salt thereof is amidated.
[0191] In some embodiments, the polypeptide or a pharmaceutically acceptable salt thereof comprises, consists of, or consists essentially of the following amino acid sequence: Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-Leu-Leu-Lys-Pro-Trp-Ala-NH2 (SEQ ID NO: 2), wherein "Ac" represents an acetyl group and the C-terminus is amidated (indicated by "NH2"). In some embodiments, the polypeptide or a pharmaceutically acceptable salt thereof comprises the amino acid sequence: Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-NH2 (SEQ ID NO: 1), wherein "Ac" represents an acetyl group and the C-terminus is amidated (represented by "NH2"). In some embodiments, the polypeptide or a pharmaceutically acceptable salt thereof comprises, consists of, or consists essentially of a sequence selected from SEQ ID NOs: 3-9, or a fragment or a pharmaceutically acceptable salt thereof.
[0192] In some embodiments, the amount of the polypeptide or its pharmaceutically acceptable salt in the composition is or is about 0.0001% to 1%, 0.0005% to 0.5%, 0.001% to 0.1%, 0.005% to 0.05%, 0.006% to 0.04%, 0.007% to 0.03%, 0.008% to 0.02%, or 0.009% to 0.01%. In one embodiment, the polypeptide or its pharmaceutically acceptable salt is present in the composition in an amount of about 0.003% to 0.09% (e.g., 0.005%, 0.01%, 0.02%, 0.03% and their ranges).
[0193] In some embodiments, the polypeptide or a pharmaceutically acceptable salt thereof is at, about, greater than, or less than 0.0001, 0.00025, 0.0005, 0.00075, 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.010, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019, 0.100, 0.111, 0.122, 0.019, 0.101 3, 0.014, 0.015, 0.020, 0.030, 0.040, 0.050, 0.060, 0.070, 0.080, 0.090, 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, or 1.0%, or an amount defined by any two of the foregoing values is present in the composition.
[0194] In some embodiments, the composition is a sterile aqueous composition comprising, consisting of, or consisting essentially of: about 0.001% to about 0.05% of a polypeptide such as Lacripep TM , or other peptides identified herein, or a pharmaceutically acceptable salt thereof; about 0.001% to about 0.015% anhydrous citric acid; about 0.02% to about 0.40% sodium citrate dihydrate; about 0.0005% to about 0.005% disodium EDTA; about 0.005% to about 0.15% tyloxapol; and optionally about 0.005% to about 0.1% methylparaben; wherein the pH of the composition is adjusted to pH about 6.2 to pH about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.1% to about 1%. In one embodiment, the composition does not contain methylparaben. In one embodiment, the composition consists solely of the listed ingredients and does not contain any additional active ingredients, excipients (e.g., viscosity building agents, buffers, chelating agents, stabilizers, preservatives, surfactants, and tonicity agents), carriers or diluents.
[0195] In some embodiments, the composition is a sterile aqueous composition comprising, consisting of, or consisting essentially of: about 0.01% ± 0.001% of a polypeptide, such as Lacripep TM , or other peptides identified herein, or a pharmaceutically acceptable salt thereof; about 0.0098% ± 0.001% anhydrous citric acid; about 0.279% ± 0.028% sodium citrate dihydrate; about 0.001% ± 0.0001% disodium EDTA; about 0.05% ± 0.005% tyloxapol; about 0.04% ± 0.004% methylparaben; wherein the pH of the composition is adjusted to about 6.2 to about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.50% ± 0.05%. In one embodiment, the composition does not contain methylparaben.
[0196] In some embodiments, the composition is a sterile aqueous composition comprising, consisting of, or consisting essentially of: about 0.005% ± 0.0005% of a polypeptide, such as Lacripep TM, or other peptides identified herein, or a pharmaceutically acceptable salt thereof; about 0.0098% ± 0.001% anhydrous citric acid; about 0.279% ± 0.028% sodium citrate dihydrate; about 0.001% ± 0.0001% disodium EDTA; about 0.05% ± 0.005% tyloxapol; about 0.04% ± 0.004% methylparaben; wherein the pH of the composition is adjusted to about 6.2 to about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.50% ± 0.05%. In one embodiment, the composition does not contain methylparaben.
[0197] In some embodiments, the composition is a sterile aqueous composition comprising: about 0.001% ± 0.0001% of a polypeptide, such as Lacripep TM , or other peptides identified herein, or a pharmaceutically acceptable salt thereof; about 0.0098% ± 0.001% anhydrous citric acid; about 0.279% ± 0.028% sodium citrate dihydrate; about 0.001% ± 0.0001% disodium EDTA; about 0.05% ± 0.005% tyloxapol; about 0.04% ± 0.004% methylparaben; wherein the pH of the composition is adjusted to about 6.2 to about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.50% ± 0.05%. In one embodiment, the composition does not contain methylparaben.
[0198] In some embodiments, including but not limited to the sterile compositions above, the polypeptide is Lacripep having SEQ ID NO: 1. TM or a pharmaceutically acceptable salt thereof. In some embodiments, the polypeptide is a polypeptide having SEQ ID NO: 2 or a pharmaceutically acceptable salt thereof. In some embodiments, the polypeptide is a polypeptide having a sequence selected from SEQ ID NO: 3-9, or a pharmaceutically acceptable salt or one or more fragments thereof.
[0199] In some embodiments, including but not limited to the sterile compositions above, the pH of the composition is from about 6.5 to about 6.6.
[0200] In some embodiments, including but not limited to the sterile compositions above, the osmotic pressure of the composition is about 280 to about 320 mOsm / kg. In some embodiments, the osmotic pressure of the composition is about 300 mOsm / kg.
[0201] In some embodiments, the composition is a sterile aqueous composition comprising: about 0.01% ± 0.001% Lacripep TM (SEQ ID NO.1) or other peptides identified herein; about 0.0098% ± 0.001% anhydrous citric acid; about 0.279% ± 0.028% sodium citrate dihydrate; about 0.001% ± 0.0001% disodium EDTA; about 0.05% ± 0.005% tyloxapol; wherein the pH of the composition is adjusted to about 6.2 to about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.50% ± 0.05%.
[0202] In some embodiments, the composition is a sterile aqueous composition comprising: about 0.005% ± 0.0005% Lacripep TM (SEQ ID NO.1) or other peptides identified herein; about 0.0098% ± 0.001% anhydrous citric acid; about 0.279% ± 0.028% sodium citrate dihydrate; about 0.001% ± 0.0001% disodium EDTA; about 0.05% ± 0.005% tyloxapol; wherein the pH of the composition is adjusted to about 6.2 to about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.50% ± 0.05%.
[0203] In some embodiments, the composition is a sterile aqueous composition comprising about 0.001% ± 0.0001% Lacripep TM (SEQ ID NO.1) or other peptides identified herein; about 0.0098% ± 0.001% anhydrous citric acid; about 0.279% ± 0.028% sodium citrate dihydrate; about 0.001% ± 0.0001% disodium EDTA; about 0.05% ± 0.005% tyloxapol; wherein the pH of the composition is adjusted to about 6.2 to about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.50% ± 0.05%.
[0204] In one embodiment, including but not limited to the above sterile composition, the composition consists only of the listed ingredients and does not contain any other active ingredients, excipients (e.g., viscosity building agents, buffers, chelating agents, stabilizers, preservatives, surfactants, and tonicity agents), carriers or diluents. In some embodiments, the amount of any one or more of the listed ingredients is provided in an amount of ±5% and / or ±1% of the listed amount.
[0205] In some embodiments, the compositions disclosed herein are prepared with solutions, gels or ointments. Compared with solutions, gels or ointments are advantageous in providing compositions that are in contact with the eyes for a long period of time, or provide other benefits. Therefore, in one embodiment, when the object is about to fall asleep, or when the eyes of the object are about to close for a long time (e.g., 1, 2, 3, 4, 5 or more hours), when the composition is applied to the object, gels or ointments are useful. Based on user preferences, gels or ointments can be used at other times.
[0206] Non-limiting exemplary compositions that can be used in the methods and kits disclosed herein include the following compositions in Table 1.1, Table 1.2, Table 1.3, and Table 1.4.
[0207] Table 1.1
[0208]
[0209]
[0210] Table 1.2
[0211]
[0212]
[0213] Table 1.3
[0214]
[0215]
[0216] Table 1.4
[0217]
[0218] Embodiments of the compositions in Tables 1.1-1.4 also include compositions in which the amount of the disclosed ingredient is within the range of ±1% of the disclosed amount, within the range of ±2% of the disclosed amount, within the range of ±3% of the disclosed amount, within the range of ±4% of the disclosed amount, or within the range of ±5% of the disclosed amount. In some embodiments, after storing the composition in Tables 1.1-1.4 at -20±5°C, 5±3°C or 25±2°C and 25±5% relative humidity for at least 1 week or 2 weeks, 1 month, 2 months, 3 months, 4 months or 5 months, in the composition, the composition retains at least about 99.0%, 99.9%, 99.95%, or 99.99% of the original undegraded form of the Lacripep polypeptide of SEQ ID NO: 1. In some embodiments, after storing the composition in Table 1.1-Table 1.4 at a temperature of -20±5°C or 5±3°C for at least 12 months, the composition retains at least about 80% or 90% of the original undegraded form of the Lacripep polypeptide of SEQ ID NO: 1. In some embodiments, the composition in Table 1.1-Table 1.4 contains about 0.2-0.8% or about 0.5% NaCl.
[0219] Other therapeutic ingredients
[0220] In some embodiments, in addition to the polypeptide disclosed herein, the composition also includes one or more additional therapeutic agents. These therapeutic agents may include substances known to those skilled in the art for the treatment of dry eye and related syndromes and conditions (including Sjögren's syndrome). Additional therapeutic ingredients may treat disease, syndrome or condition, or may alleviate symptoms associated with disease, syndrome or condition. In addition, a non-exhaustive list of therapeutic agents includes: cholinergic drugs (e.g., pilocarpine, cevimeline), cyclosporine, rifalast, dexamethasone (or other corticosteroids, such as prednisolone), hyaluronic acid (and derivatives thereof) containing or not containing chondroitin sulfate, Cyclokat, SI-614, skQ1, cis-UCA, CycloASol, RGN-259, diquafosol, anakinra, tofacitinib, EBI-005, EGP-437, KP-121, MIM-D3, OTX-DP, rebamipide (OPC-12759) and RU-101. In some embodiments, the additional therapeutic agent is Xiidra (Lifalast, SAR-1118). In some embodiments, one or more additional therapeutic agents are provided as salts of polypeptides. Artificial tears containing one or more of carboxymethylcellulose, polyvinyl alcohol, hydroxypropyl methylcellulose (also known as HPMC or hydroxypropyl methylcellulose), hydroxypropyl cellulose, ethylene glycol polymers, and hyaluronic acid (also known as hyaluronic acid, HA) and other lubricants and tear ointments (such as white petrolatum, mineral oil and similar lubricants) may also be included in the composition. These additional therapeutic agents may be included in known therapeutic or subtherapeutic amounts.
[0221] Containers and kits
[0222] In some embodiments, compositions are provided in a test kit comprising one or more multiple use containers. In some embodiments, the multiple use container comprises a protective cap and a liquid storage bottle, wherein the cap is connected to the bottom via a flexible connector. The sealing plug is arranged in the middle part of the protective cap upper surface. The liquid outlet of a cone or other suitable shape is arranged in the middle part of the bottle cap and closely cooperates with the sealing plug of the protective cap. Therefore, the sterile composition can be placed in a container for multiple use.
[0223] In some embodiments, the amount of the composition in the container is or is about: 0.1-0.5, 0.5-1.0, 1-2, 2-5, 5-10, 10-20, 20-30, or 30-60 mL or a range therebetween. The container can be a bottle, tube, vial or other suitable container. Multiple-use containers can be accompanied by instructions for use for a period of 12 hours, 24 hours, 2-7 days, 1 month, or until a specified expiration date. Disposable containers can be suitable for a single application cycle for one eye or both eyes.
[0224] In some embodiments, the composition is provided in a kit comprising a disposable container. In some embodiments, the composition is provided in a kit comprising a plurality of disposable containers. In some embodiments, the disposable container comprises: a vessel for holding a liquid, a removable sealing top for sealing the vessel, and optionally a neck interconnecting the vessel and the sealing top. In several embodiments, a kit comprising a plurality of disposable containers together with instructions for use is provided.
[0225] In some embodiments, the container comprises a pharmaceutically inert material. In some embodiments, the container comprises glass, polyvinyl chloride, polypropylene, polyethylene terephthalate, polyethylene terephthalate, polyethylene terephthalate G, high density polyethylene, low density polyethylene, polybutylene terephthalate, polyurethane, polyethylene vinyl acetate, silicone, acrylonitrile butadiene styrene, polytetrafluoroethylene, polycarbonate, polystyrene, polymethyl methacrylate, polysulfone, polyvinylidene chloride, or a combination thereof.
[0226] In some embodiments, the container comprises polyvinyl chloride, polypropylene, low density polyethylene, polyurethane, polyethylene vinyl acetate, silicone, or a combination thereof.
[0227] In some embodiments, the amount of the composition in the container is or is about 0.02 mL, 0.05 mL to 1 mL, 0.1 mL to 0.95 mL, 0.15 mL to 0.8 mL, 0.2 mL to 0.85 mL, 0.25 mL to 0.8 mL, 0.3 mL to 0.75 mL, 0.35 mL to 0.7 mL, 0.4 mL to 0.65 mL, 0.45 mL to 0.6 mL, 0.5 mL to 0.55 mL, or any amount therebetween.
[0228] In some embodiments, the amount of the composition in the container is or is about 0.02 mL, 0.025 mL, 0.030 mL, 0.035 mL, 0.040 mL, 0.045 mL, 0.050 mL, 0.055 mL, 0.060 mL, 0.065 mL, 0.070 mL, 0.075 mL, 0.1 mL, 0.15 mL, 0.2 mL, 0.25 mL, 0.3 mL, 0.35 mL, 0.4 mL, 0.45 mL, 0.5 mL, 0.55 mL, 0.6 mL, 0.65 mL, 0.7 mL, 0.75 mL, 0.8 mL, 0.85 mL, 0.9 mL, 0.95 mL, or 1 mL, or an amount within a range defined by any two of the foregoing values.
[0229] Ophthalmic and other drug delivery
[0230] In some embodiments, the composition is topically administered to the eye. In some embodiments, the composition is administered to an individual suffering from any form of dry eye or dry eye associated with Sjögren's syndrome (or other symptoms, such as dry mouth) for treatment thereof. In some embodiments, the composition is administered to the oral cavity as a gargle, tablet, patch, spray or lozenge. The composition described herein may be provided in a liquid (solution, gel, ointment, etc.) or in other suitable forms (such as powders or patches, tablets, etc.). In some embodiments, the composition described herein is used to achieve one or more of the following: restore basal tearing, salivation, general mucosal and ocular surface moistening; restore ocular surface and mucosal homeostasis, rapidly but transiently promote autophagy to eliminate pressure, stress or degenerative diseases in the eye and other organs; reduce inflammation, promote wound healing (such as corneal refractive surgery or oral wound healing), stabilize the tear lipid layer and inhibit bacterial infection.
[0231] In some embodiments, administering topically to the eye comprises administering one or more drops of the composition to the surface of the eye. For example, in one embodiment, the user is instructed to apply to the surface of the eye, not to a contact lens). In other embodiments, the drops (or other applications) are suitable for administration while wearing contact lenses. In some embodiments, the composition is administered from a container in a single dose delivered to each eye as a single drop. In some embodiments, the volume of the drops is about 0.020 mL to about 0.050 mL, or any volume therebetween. In some embodiments, the drops are about 0.035 mL.
[0232] In some embodiments, administering the composition to the eye improves one or more patient-reported symptoms or clinical signs of dry eye or Sjögren's syndrome. Improvement of dry eye symptoms or signs can be assessed by one or more of the following:
[0233] Fluorescein corneal staining (FCS) (0 to 3 scales per region, 5 regions, 0-15 scales total, using NEI / industry workshop scale)
[0234] Lissamine green conjunctival staining (LGCS) (0 to 3 scale by region, 0-18 scale total, using NEI / industry workshop scale)
[0235] Anesthetized tear secretion test (mm wetted within 5 minutes)
[0236] Tear film breakup time (seconds)
[0237] Eye dryness reported by patients on a visual analogue scale and tabulated as mean change from baseline
[0238] • Dry Eye Related Ocular Symptoms Questionnaire (SANDE: Frequency and Severity of Dry Eye Symptoms), (Schaumberg D et al. Development and Validation of a Short Global Dry Eye Symptom Index. The Ocular Surface. January 2007, Vol. 5; No. 1; pp. 50-57, which is hereby incorporated by reference in its entirety).
[0239] In some embodiments, the composition is a sterile aqueous composition comprising, consisting of, or consisting essentially of: about 0.001% to about 0.05% Lacripep TM (SEQ ID NO.1) or other peptides identified herein; about 0.001% to about 0.015% anhydrous citric acid; about 0.02% to about 0.40% sodium citrate dihydrate; about 0.0005% to about 0.005% disodium EDTA; about 0.005% to about 0.15% tyloxapol, and about 0.005% to about 0.1% methylparaben; wherein the pH of the composition is adjusted to pH about 6.2 to pH about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.1% to about 1%. In one embodiment, the composition does not contain methylparaben. In one embodiment, the composition consists solely of the listed ingredients and does not contain any additional active ingredients, excipients (eg, viscosity building agents, buffers, chelating agents, stabilizers, preservatives, surfactants, and tonicity agents), carriers or diluents.
[0240] In some embodiments, the composition is a sterile aqueous composition comprising, consisting of, or consisting essentially of: about 0.001% to about 0.05% Lacripep TM(SEQ ID NO.1) or other peptides identified herein; about 0.001% to about 0.015% anhydrous citric acid; about 0.02% to about 0.40% sodium citrate dihydrate; about 0.0005% to about 0.005% disodium EDTA; and about 0.005% to about 0.15% tyloxapol; wherein the pH of the composition is adjusted to pH about 6.2 to pH about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.1% to about 1%. In one embodiment, the composition consists solely of the listed ingredients and does not contain any additional active ingredients, excipients (e.g., viscosity building agents, buffers, chelating agents, stabilizers, preservatives, surfactants, and tonicity agents), carriers, or diluents.
[0241] In some embodiments, the composition is a sterile aqueous composition comprising about 0.01% ± 0.001% Lacripep TM (SEQ ID NO.1) or other peptides identified herein; about 0.0098% ± 0.001% anhydrous citric acid; about 0.279% ± 0.028% sodium citrate dihydrate; about 0.001% ± 0.0001% disodium EDTA; about 0.05% ± 0.005% tyloxapol; wherein the pH of the composition is adjusted to about 6.2 to about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.50% ± 0.05%.
[0242] In some embodiments, the composition is a sterile aqueous composition comprising: about 0.005% ± 0.0005% Lacripep TM (SEQ ID NO.1) or other peptides identified herein; about 0.0098% ± 0.001% anhydrous citric acid; about 0.279% ± 0.028% sodium citrate dihydrate; about 0.001% ± 0.0001% disodium EDTA; about 0.05% ± 0.005% tyloxapol; wherein the pH of the composition is adjusted to about 6.2 to about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.50% ± 0.05%.
[0243] In some embodiments, the composition is a sterile aqueous composition comprising about 0.001% ± 0.0001% Lacripep TM(SEQ ID NO.1) or other peptides identified herein; about 0.0098% ± 0.001% anhydrous citric acid; about 0.279% ± 0.028% sodium citrate dihydrate; about 0.001% ± 0.0001% disodium EDTA; about 0.05% ± 0.005% tyloxapol; wherein the pH of the composition is adjusted to about 6.2 to about 6.8 with NaOH or HCl, and the osmotic pressure of the composition is adjusted to about 250 to about 350 mOsm / kg with NaCl. In some embodiments, the amount of NaCl is about 0.50% ± 0.05%.
[0244] Some embodiments include a method of treating dry eye and / or primary Sjögren's syndrome; comprising administering a composition disclosed herein to the eye of a subject suffering from dry eye and / or primary Sjögren's syndrome. In one embodiment, the composition described herein is used to treat Sjögren's syndrome. In some embodiments, the composition described herein is used to treat a subject that meets one or more of the following criteria:
[0245] I. Eye symptoms
[0246] o Have dry eye symptoms for at least 3 months
[0247] o Feeling of a foreign body in the eye
[0248] o Use artificial tears 3 or more times a day
[0249] II. Oral symptoms
[0250] o Have dry mouth symptoms for at least 3 months
[0251] o Recurrent or persistent swelling of the salivary glands
[0252] o Need liquids when swallowing dry food
[0253] III. Ocular signs
[0254] o Abnormal anesthesia tear secretion test (no anesthesia; ≤ 5 mm / 5 minutes)
[0255] o Positive vital dye staining of the eye surface
[0256] IV. Histopathology
[0257] o Lip biopsy showing focal lymphocytic sialadenitis (focal score ≥ 1 / 4 mm 2 )
[0258] V. Oral signs
[0259] o Unstimulated total salivary flow (≤ 1.5 mL in 15 minutes)
[0260] o Abnormal parotid gland imaging
[0261] o Abnormal salivary gland scan
[0262] VI. Autoantibodies
[0263] o Anti-SSA (Ro) (anti-Sjögren's syndrome-associated antigen A) or anti-SSB (La) (anti-Sjögren's syndrome-associated antigen B), or both.
[0264] In one embodiment, the compositions described herein are used to treat a subject having at least one criterion from each of the above 6 categories. In some embodiments, the polypeptide or pharmaceutically acceptable salt thereof in the composition is Lacripep TM (having a sequence consisting of Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-NH2, wherein "Ac" represents an acetyl group and the C-terminus is amidated in an amount of 0.005% or 0.01% (SEQ ID NO: 1)). In some embodiments, in addition to the polypeptide (e.g., Lacripep TM ), the ophthalmic solution further comprises citric acid (about 0.0098% anhydrous), sodium citrate (about 0.279% sodium citrate dehydrate), disodium EDTA (about 0.001%), NaCl (to about 300 mOsm / kg), tyloxapol (about 0.05%), NaOH (to about pH 6.5), purified water, USP. To assess efficacy, some embodiments employ a placebo comprising a vehicle ophthalmic solution and no polypeptide. In some embodiments, one drop of the composition is administered to the eye of the subject up to three times daily. In some embodiments, administration improves the FCS overall score (NEI / Industry Workshop 0-15 scale) in the eye of the subject after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or after at least 6 weeks from the start of the 4 weeks of treatment, compared to a baseline measurement prior to the start of treatment. In some embodiments, administration improves one or more of the following:
[0265] Dry eyes after at least 2 weeks of treatment, or after at least 4 weeks of treatment, compared with baseline on a visual analogue scale;
[0266] SANDE after at least 2 weeks of treatment (overall score SANDE-1) compared with baseline measurement before starting treatment;
[0267] Mean SANDE score (overall score SANDE-1) after at least 2 weeks of treatment compared with baseline measurement before starting treatment;
[0268] Individual symptom assessments (momentary) after at least 2 weeks of treatment compared to baseline measurements before starting treatment;
[0269] Mean scores of individual symptom assessments after at least 2 weeks of treatment compared to baseline measurements before starting treatment (reflected);
[0270] LGCS in the subject's eye after at least 2 weeks of treatment compared to baseline measurements before starting treatment;
[0271] Anesthetized tear secretion test in the subject's eyes after at least 2 weeks of treatment compared to baseline measurements before starting treatment;
[0272] TFBUT in the subject's eye after at least 2 weeks of treatment compared to a baseline measurement prior to starting treatment;
[0273] the FCS in the subject's eye after at least 2 weeks of treatment compared to the baseline measurement before starting treatment;
[0274] SANDE (SANDE-1 global score) at 1 week after at least 2 weeks of treatment, or at least 4 weeks of treatment, or after 4 weeks of treatment, compared with baseline measurement before starting treatment;
[0275] Individual symptoms (transient) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared to baseline measurements before starting treatment;
[0276] Mean score (SANDE-2 global score) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared with baseline measurement before starting treatment;
[0277] Mean scores on individual symptom assessments (reflected) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared to baseline measurements before starting treatment;
[0278] FCS and SANDE1 and individual symptom assessments (momentary) after at least 2 weeks of treatment, or after at least 4 weeks of treatment compared to baseline measurements before initiation of treatment;
[0279] LGCS after at least 2 weeks of treatment, or after at least 4 weeks of treatment, compared with baseline measurement before starting treatment;
[0280] Anesthetized tear test results after at least 2 weeks of treatment, or after at least 4 weeks of treatment, compared to baseline measurements before starting treatment;
[0281] TFBUT after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared to the baseline measurement before starting treatment.
[0282] In some embodiments, the comparison is instead of or also includes comparison to a vehicle control.
[0283] In one embodiment, any one or more of the following drugs / therapies are not co-administered with a composition described herein, and in one embodiment, any one or more of the following drugs / therapies are co-administered with a composition described herein:
[0284] Ophthalmic medications (any topical eye medication), both prescription and over-the-counter [OTC]
[0285] Contact lenses
[0286] Any ocular surface or eyelid surgery within 365 days before the start of treatment, or any intraocular surgery within 90 days before the start of treatment
[0287] Amiodarone
[0288] Topical ophthalmic antihistamines
[0289] Ophthalmic, inhaled, or intranasal corticosteroids
[0290] Topical or oral mast cell stabilizers
[0291] Oral antihistamines
[0292] Topical or nasal vasoconstrictors
[0293] Topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs)
[0294] Topical ophthalmic antibiotics
[0295] Within 60 days prior to treatment and / or during treatment: topical cyclosporine, topical ritalidomide. Within 90 days prior to treatment and / or during treatment: punctal cautery or change (insertion or removal) of punctal plugs or nasolacrimal duct surgery.
[0296] Long-term oral antiviral medication for ocular herpetic disease. Example
[0297] The following are non-limiting examples of some embodiments described herein.
[0298] Example 1: Peptide Composition Stability
[0299] Several Lacripep products were tested at -20°C, 5°C, 25°C / 25% relative humidity, or 25°C / 60% relative humidity for 1 week, 2 weeks, 1 month, 2 months, 3 months, 4 months, and 12 months. TM (SEQ ID NO. 1) Stability of ophthalmic formulations. These formulations are shown in Table 1.5, and the stability data are shown in Table 2 (degradation products are indicated as Lacripep TM In the table below (w / w percentage of the initial amount of ) and Table 3 (12 month data). Under all test conditions, each formulation remained a clear colorless solution, and the packaging did not leak or change color.
[0300] Table 1.5 - Lacripep used for stability studies TM preparation
[0301]
[0302] Table 2 - Lacripep TM Formulation stability, pH and degradation product % w / w
[0303]
[0304]
[0305] Table 3 - Lacripep at 12 months, 5°C TM Stability of formulation
[0306]
[0307] RRT = relative retention time
[0308] Example 2. Comparative Peptide Stability
[0309] In PBS at pH 4.5 and 7.0 ( Figure 1 ) and in citrate buffer at pH 6.0 and 6.5 ( Figure 2 ) Evaluation of Lacripep TM (SEQ ID NO.1) stability. TM The initial concentration of was 0.001%, and each test was run at 60°C. At the beginning of the experiment (week 0, Figure 1 and Figure 2 ) and 2 weeks later (week 2, Figure 1 and Figure 2 The stability of the samples was evaluated by MALDI TOF mass spectrometry. TMSignificant degradation was observed in the peaks (large arrows), such as new lower m / e peaks, for example at 993.9 (m / e) (small arrows, Figure 1 In contrast, after 2 weeks in citrate buffer at pH 6.0 and 6.5, there was no Lacripep TM changes in peak intensity (large arrows), or the appearance of any new lower m / e peaks ( Figure 2 , lower panel). This indicates an unexpected improvement in peptide stability in citrate buffer.
[0310] Example 3: Composition manufacturing process
[0311] Table 4 summarizes the following process.
[0312] In an appropriately sized manufacturing vessel, add sterile purified water (Part I) and methylparaben. Heat the mixture to 65°C ± 5°C with propeller mixing until the methylparaben is dissolved and a clear solution is obtained, then remove the heat. If necessary, the mixture may be heated up to 80°C ± 2°C to obtain a clear solution.
[0313] With further continued propeller mixing, add citric acid, sodium citrate, and disodium EDTA. Mix until all three ingredients are dissolved, a clear solution is obtained and the temperature of the solution is below 22°C ± 2°C.
[0314] With further continuous propeller mixing, Tyloxapol and Lacripep were added. TM (SEQ ID NO. 1) and mixed until a clear solution was obtained.
[0315] If necessary, adjust the pH of the bulk solution to 6.5 ± 0.3 with 10% NaOH (aq.) or 10% HCl (aq.) Mix until the solution is homogeneous.
[0316] When necessary, the osmotic pressure of the solution was adjusted to 300 ± 20 mOsm / kg with 25% NaCl (aq).
[0317] Add purified water (Part II) to the batch to q. 100%. Mix with propeller until solution is homogeneous.
[0318] Table 4 - Process (A)
[0319]
[0320]
[0321] Example 4. Composition manufacturing process, preservative-free composition
[0322] The following process is summarized in Table 5.
[0323] In an appropriately sized manufacturing vessel, add purified water (Part I).
[0324] With continuous propeller mixing, add citric acid, sodium citrate and disodium EDTA. Mix until all three ingredients are dissolved, a clear solution is obtained and the temperature of the solution is below 22°C ± 2°C.
[0325] With further continuous propeller mixing, Tyloxapol and Lacripep were added. TM (SEQ ID NO. 1) and mixed until a clear solution was obtained.
[0326] If necessary, adjust the pH of the bulk solution to 6.5 ± 0.3 with 10% NaOH (aq.) or 10% HCl (aq.) Mix until the solution is homogeneous.
[0327] If necessary, the osmotic pressure of the solution was adjusted to 300 ± 20 mOsm / kg with 25% NaCl (aq).
[0328] Table 5. Process (B)
[0329]
[0330] Example 5. Composition manufacturing process
[0331] Table 6 summarizes the following process.
[0332] In an appropriately sized manufacturing vessel, add purified water (Part I). With continuous propeller mixing, add citric acid, sodium citrate, and disodium EDTA. Mix until all three ingredients are dissolved, a clear solution is obtained, and the temperature of the solution is less than 22°C ± 2°C.
[0333] With further continuous propeller mixing, Tyloxapol and Lacripep were added. TM (SEQ ID NO. 1) and mix until a clear solution is obtained. If necessary, adjust the pH of the bulk solution to 6.5 ± 0.3 with 10% NaOH (aqueous solution) or 10% HCl (aqueous solution). Mix until the solution is homogeneous.
[0334] When necessary, the osmotic pressure of the solution was adjusted to 300 ± 20 mOsm / kg with 25% NaCl (aq).
[0335] Table 6. Process (C)
[0336]
[0337] For example, the composition comprises less than 0.05% of an active ingredient, such as a polypeptide (e.g., 0.001-0.02%, 0.001-0.05%) or a pharmaceutically acceptable salt thereof; and one or more of: (i) less than 0.6% of a buffer (e.g., 0.001-.3%, 0.001-0.6%); (ii) less than 0.01% of disodium EDTA (e.g., 0%, 0.001-.005%, 0.001-0.01%); and (iii) less than 0.1% of tyloxapol (e.g., 0%, 0.001-0.05%, 0.001-0.1%), and optionally other ingredients.
[0338] In addition, although the foregoing has been described in detail by way of illustration and example for the purpose of clarity and understanding, it will be appreciated by those skilled in the art that various modifications may be made without departing from the spirit of the present disclosure. Therefore, it should be clearly understood that the forms disclosed herein are merely illustrative and are not intended to limit the scope of the present disclosure, but also encompass all modifications and substitutions that come with the true scope and spirit of the embodiments of the present invention.
[0339] Unless otherwise expressly stated, the terms and phrases used in this application and their variations, especially in the appended claims, should be interpreted as open-ended rather than restrictive. As the aforementioned example, the term "comprising" should be interpreted as meaning "including but not limited to", "including but not limited to", etc.
[0340] The indefinite article "a" or "an" does not exclude a plurality. The use of "about" before a number includes the number itself. For example, "about 5" provides expressive support for "5".
Claims
1. A liquid composition comprising: 0.00001-0.1%, or 0.001-0.05% of a polypeptide or a pharmaceutically acceptable salt thereof; 0.01-0.6% buffer; None or 0.0005-0.01% disodium EDTA; None or 0.01-0.1% tyloxapol; and sodium chloride; wherein the pH of the composition is from 6.2 to about 6.8, and the osmotic pressure of the composition is from about 250 to 350 mOsm / kg.
2. The composition according to claim 1, wherein the polypeptide or a pharmaceutically acceptable salt thereof is 0.01% or 0.005%; wherein the buffer is 0.25-0.31%, or 0.2888%; wherein the disodium EDTA is 0.001%; wherein the tyloxapol is 0.05%; wherein the pH of the composition is from 6.2 to about 6.8, and the osmotic pressure of the composition is from about 250 to 350 mOsm / kg; The polypeptide is Lacripep having SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof.
3. The composition according to any one of claims 1 to 2, wherein the buffer is a citrate buffer.
4. The composition of claim 3, wherein the citrate buffer comprises 0.0098% anhydrous citric acid and 0.279% sodium citrate dihydrate.
5. The composition of any one of claims 1 to 4, wherein the pH of the composition is about 6.
5.
6. The composition according to any one of claims 1 to 5, wherein the composition has an osmotic pressure of 280 to 320 mOsm / kg.
7. The composition according to any one of claims 1 to 6, wherein the osmotic pressure of the composition is 300 mOsm / kg.
8. The composition according to any one of claims 1 to 7, wherein the amount of NaCl is between 0.4% and 0.6%.
9. The composition according to any one of claims 1 to 8, wherein the amount of NaCl is 0.5%.
10. The composition according to any one of claims 1 to 9, wherein the composition further comprises 0.04% methylparaben.
11. The composition according to any one of claims 1 to 10, wherein the composition is sterile.
12. A kit comprising a plurality of disposable containers, wherein each container comprises a vessel for containing the composition of any one of claims 1 to 11.
13. The kit of claim 12, wherein the container comprises about 0.05 mL to about 1 mL of the composition.
14. The kit according to any one of claims 12 to 13, wherein the container comprises a removable sealing top for sealing the vessel and a neck interconnecting the vessel and the sealing top.
15. The kit of claim 14, wherein the removable sealing top is incapable of resealing the vessel once removed.
16. The kit of any one of claims 12 to 15, wherein the container comprises polyvinyl chloride, polypropylene, polyethylene terephthalate, polyethylene terephthalate, polyethylene terephthalate G, high density polyethylene, low density polyethylene, polybutylene terephthalate, polyurethane, polyethylene vinyl acetate, silicone, acrylonitrile butadiene styrene, polytetrafluoroethylene, polycarbonate, polystyrene, polymethyl methacrylate, polysulfone, polyvinylidene chloride, or a combination thereof.
17. A method of administration comprising topically applying one or more drops of a composition according to any one of claims 1 to 11 to the eye.
18. The method of claim 17, wherein the administering further comprises topically applying drops of the composition to the eye from a single-use container from any one of claims 12 to 16.
19. Use of the composition of any one of claims 1 to 11 for treating dry eyes.
20. Use of a composition as claimed in any one of claims 1 to 11 for treating one or more symptoms of Sjögren's syndrome.
21. A topical composition comprising: 0.005-0.05% of a polypeptide and one or more of the following: 0.1-0.6% buffer; 0.0005-0.01% disodium EDTA; 0.01-0.1% tyloxapol; and sodium chloride; The composition is a solution, a gel or an ointment.
22. The composition of claim 21, wherein the polypeptide is provided in an amount of 0.001 to 0.01%.
23. The composition of claim 21 or 22, wherein the polypeptide is a tear glycoprotein or a fragment thereof.
24. The composition of claims 21 to 23, wherein the polypeptide is any one of SEQ ID NOs: 1-9.
25. The composition of claims 21 to 24, wherein the polypeptide is Lacripep.
26. A composition according to claims 21 to 25 for use in treating dry eyes or one or more symptoms of Sjögren's syndrome.
27. A method of treating dry eye and / or primary Sjögren's syndrome, comprising administering the composition of any one of the preceding claims to the eye of a subject suffering from dry eye and / or primary Sjögren's syndrome; wherein the amount of the polypeptide or a pharmaceutically acceptable salt thereof is 0.005% or 0.01%; wherein the polypeptide has a sequence consisting of Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-NH2, wherein "Ac" represents an acetyl group and the C-terminus is amidated (SEQ ID NO: 1); and wherein one drop of the composition is administered to the subject's eye up to three times daily.
28. The method of claim 27, wherein the administering improves the FCS total score (NEI / Industry Workshop 0-15 scale) in the subject's eye after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or after at least 6 weeks from the start of 4 weeks of treatment, compared to a baseline measurement before initiation of treatment.
29. The method of claims 27 to 28, wherein the administration improves one or more of the following: Dry eyes after at least 2 weeks of treatment, or after at least 4 weeks of treatment, compared with baseline on a visual analogue scale; SANDE after at least 2 weeks of treatment (overall score SANDE-1) compared with baseline measurement before starting treatment; Mean SANDE score (overall score SANDE-1) after at least 2 weeks of treatment compared with baseline measurement before starting treatment; Individual symptom assessments (momentary) after at least 2 weeks of treatment compared to baseline measurements before starting treatment; Mean scores of individual symptom assessments after at least 2 weeks of treatment compared to baseline measurements before starting treatment (reflected); LGCS in the subject's eye after at least 2 weeks of treatment compared to baseline measurements before starting treatment; Anesthetized tear secretion test in the subject's eyes after at least 2 weeks of treatment compared to baseline measurements before starting treatment; TFBUT in the subject's eye after at least 2 weeks of treatment compared to a baseline measurement prior to starting treatment; the FCS in the subject's eye after at least 2 weeks of treatment compared to the baseline measurement before starting treatment; SANDE (SANDE-1 global score) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared with baseline measurement before starting treatment; Individual symptoms (transient) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared to baseline measurements before starting treatment; Mean score (SANDE-2 global score) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared with baseline measurement before starting treatment; Mean scores on individual symptom assessments (reflected) after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared to baseline measurements before starting treatment; FCS and SANDE1 and individual symptom assessments (momentary) after at least 2 weeks of treatment, or after at least 4 weeks of treatment compared to baseline measurements before initiation of treatment; LGCS after at least 2 weeks of treatment, or after at least 4 weeks of treatment, compared with baseline measurement before starting treatment; Anesthetized tear test results after at least 2 weeks of treatment, or after at least 4 weeks of treatment, compared to baseline measurements before starting treatment; TFBUT after at least 2 weeks of treatment, or after at least 4 weeks of treatment, or 1 week after 4 weeks of treatment, compared to the baseline measurement before starting treatment.
30. The method of any one of claims 27 to 29, wherein administration of the composition to a group of subjects does not result in an incidence of adverse events that is significantly greater than the incidence of adverse events when a placebo is administered to a similar group of subjects.
31. The method of any one of claims 27 to 29, wherein administration of the composition to a group of subjects does not result in an incidence of adverse events that is statistically greater than the incidence of adverse events when a placebo is administered to a similar group of subjects.
32. The method of any one of claims 27 to 29, wherein administration of the composition to a group of subjects does not result in a rate of serious adverse events that is statistically greater than the rate of serious adverse events when a placebo is administered to a similar group of subjects.
33. The method of any one of the preceding claims, wherein the concentration of the polypeptide or a pharmaceutically acceptable salt thereof is about 0.005%.
34. The method of any one of the preceding claims, wherein the concentration of the polypeptide or a pharmaceutically acceptable salt thereof is about 0.01%.
35. The method of any of the preceding claims, wherein the subject meets all of the following criteria: Aged 18 or above; A previous history or current diagnosis of primary Sjögren's syndrome documented according to the American-European Consensus Group Sjögren's syndrome criteria, with 4 of the 6 total criteria or 3 of the 4 signs; If the subject is receiving systemic (oral) therapy for the treatment of Sjögren's syndrome, the subject must have been receiving stable systemic therapy, defined as the same therapy, for the exact preceding 90 days; A history of dry eye-related ocular symptoms and self-reported use of over-the-counter ocular lubricants in the past 120 days; and Before starting treatment, all of the following criteria were met: (a) Fluorescein corneal staining (FCS) total score ≥4 and <15 (where 0 = no staining) on the National Eye Institute (NEI) / Industry Workshop scale; (b) symptom score ≥40 using the SANDE questionnaire; (c) anesthesia tear secretion test score ≤ 5 mm wetting / 5 min; (d) Lissamine green conjunctival staining (LGCS) total score using the NEI / Industry Workshop Scale ≥5 (where 0 = no staining); The subjects had to meet all 4 criteria in at least one and the same eye at the time of follow-up.
36. The method of any of the preceding claims, wherein the subject does not meet one or more of the following criteria: Any active infectious eye condition; Monocular or best-corrected visual acuity (BCVA), with corrective lenses if necessary, of +1.0 logMAR or worse, as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS); Ocular inflammatory conditions not related to dry eye syndrome (e.g., conjunctivitis, keratitis, anterior blepharitis, etc.); Clinical evidence of scarring ocular surface disease, such as scarring ocular pemphigoid or Stevens-Johnson syndrome; During treatment with the composition, the use of any topical ophthalmic medication (including topical cyclosporine) should not be suspended; Used within 60 days before starting treatment with the composition (topical ophthalmic cyclosporine); Used within 60 days before starting treatment with the composition (topical ophthalmic lifalast); The subject's eye has a total fluorescein corneal staining (FCS) score = 15 or a score = 3 on the upper zone NEI / Industry Workshop scale, or the subject's eye has diffuse confluent staining, filamentous, or obvious epithelial defects; Active herpetic keratitis or an outbreak of herpetic keratitis within 365 days of starting treatment, or the subject is taking long-term oral antiviral medication for herpetic disease; Do not suspend or avoid contact lens use during treatment; Have a history of collagen vascular disease, autoimmune disease, or rheumatic disease (e.g., lupus, rheumatoid arthritis, etc.) other than primary Sjögren's syndrome; A history of or current anterior membrane dystrophy; Have undergone corneal transplant or similar corneal surgery (DALK, DSEK, DMEK, etc.); Used or expected to use amiodarone; Changes in the dose of any of the following within 30 days prior to starting treatment or anticipated changes in the dose of any of the following: tetracycline, omega-3, or omega-6; Changes in the doses of the following within 60 days before starting treatment and / or during treatment or anticipated changes in the doses of the following: anticholinergics, antidepressants, oral contraceptives, isotretinoin, oral systemic corticosteroids, oral systemic immunosuppressants; Use of topical ophthalmic antihistamines, ophthalmic, inhaled or intranasal corticosteroids, topical or oral mast cell stabilizers, oral antihistamines, topical or nasal vasoconstrictors, topical ophthalmic nonsteroidal anti-inflammatory drugs, or topical ophthalmic antibiotics within 30 days before starting treatment and / or during the study; Punctal cautery has been performed in the subject's eye within the past 90 days or a punctal plug has been changed (inserted or removed) prior to starting treatment; The subject has undergone corneal refractive surgery (LASIK, PRK, RK) in his / her eye; Any history of any surgical procedure on the ocular surface or eyelid within 365 days prior to starting treatment, and any history of intraocular surgery within 90 days prior to starting treatment; Pregnancy or suspected pregnancy; are breastfeeding or plan to breastfeed; and Participation in a device or investigational drug research or clinical trial within 30 days of starting treatment.
37. The composition, kit or method of any of the preceding claims, wherein the polypeptide has a sequence consisting of Ac-Lys-Gln-Phe-Ile-Glu-Asn-Gly-Ser-Glu-Phe-Ala-Gln-Lys-Leu-Leu-Lys-Lys-Phe-Ser-NH2, wherein "Ac" represents an acetyl group and the C-terminus is amidated (SEQ ID NO: 1).
38. The composition, kit or method of any preceding claim, wherein the amount of the polypeptide or a pharmaceutically acceptable salt thereof is 0.01% or 0.005%.
39. A composition, kit or method according to any preceding claim, wherein the comparison to a baseline measurement prior to initiation of treatment is instead of or also includes a comparison of treatment with the polypeptide relative to a vehicle control.
40. A composition, kit or method according to any one of the preceding claims, wherein the composition comprises: 0.001-0.05% polypeptide or a pharmaceutically acceptable salt thereof; 0.01-0.6% buffer; 0.0005-0.01% disodium EDTA; 0.01-0.1% tyloxapol, and sodium chloride; wherein the pH of the composition is from 6.2 to about 6.8, and the osmotic pressure of the composition is from about 250 to 350 mOsm / kg.
41. The composition, kit or method of claim 40, wherein the polypeptide or a pharmaceutically acceptable salt thereof is 0.01%; wherein the buffer is 0.2888%; wherein the disodium EDTA is 0.001%; wherein the tyloxapol is 0.05%, wherein the pH of the composition is from 6.2 to about 6.8, and the osmotic pressure of the composition is from about 250 to 350 mOsm / kg. The polypeptide is Lacripep having SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof.
42. The composition, kit or method of any preceding claim, wherein the composition does not contain tyloxapol.
43. The composition, kit or method of any preceding claim, wherein the composition does not contain EDTA.
44. The composition, kit or method of any of the preceding claims, wherein the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition after storage of the composition at 5±3°C or 25±2°C and 25±5% relative humidity for 1 week.
45. The composition, kit or method of any of the preceding claims, wherein the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition after storage of the composition at 25±2°C and 25±5% relative humidity for 2 weeks.
46. The composition, kit or method of any of the preceding claims, wherein the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition after storage of the composition at 5±3°C or 25±2°C and 25±5% relative humidity for 1 month.
47. The composition, kit or method of any of the preceding claims, wherein the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition after storage of the composition at 5±3°C for 2 months.
48. The composition, kit or method of any of the preceding claims, wherein the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition after storage of the composition at 5±3°C or -20±5°C for 3 months.
49. The composition, kit or method of any of the preceding claims, wherein the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition after storage of the composition at 5±3°C for 4 months.
50. The composition, kit or method of any of the preceding claims, wherein the composition retains at least about 99.0% of the polypeptide in undegraded form in the composition after storage of the composition at 5±3°C for 5 months.
51. The composition, kit or method of any one of claims 44 to 50, wherein the composition retains at least about 99.5% of the polypeptide in undegraded form in the composition.
52. The composition, kit or method of any one of claims 44 to 50, wherein the composition retains at least about 99.9% of the polypeptide in undegraded form in the composition.
53. The composition, kit or method of any one of claims 44 to 50, wherein the composition retains at least about 99.95% of the polypeptide in undegraded form in the composition.
54. The composition, kit or method of any of the preceding claims, wherein the composition retains at least about 80% of the polypeptide in undegraded form in the composition after storage of the composition at 5±3°C for 12 months.
55. The composition, kit or method of claim 54, wherein said composition retains at least about 90% of said polypeptide in an undegraded form in said composition.
